These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21785677)

  • 1. Influence of histocompatibility genes on disease susceptibility and treatment response in patients with relapsing-remitting multiple sclerosis treated with interferon β-1a.
    Flechter S; Klein T; Pollak L
    Neurol Int; 2011 Jun; 3(1):e5. PubMed ID: 21785677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews.
    Kwon OJ; Karni A; Israel S; Brautbar C; Amar A; Meiner Z; Abramsky O; Karussis D
    Arch Neurol; 1999 May; 56(5):555-60. PubMed ID: 10328250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA genes as modifiers of response to IFN-β-1a therapy in relapsing-remitting multiple sclerosis.
    Mazdeh M; Taheri M; Sayad A; Bahram S; Omrani MD; Movafagh A; Inoko H; Akbari MT; Noroozi R; Hajilooi M; Solgi G
    Pharmacogenomics; 2016 Apr; 17(5):489-98. PubMed ID: 27020477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis: disease modifying therapy and the human leukocyte antigen.
    Werneck LC; Lorenzoni PJ; Kay CSK; Scola RH
    Arq Neuropsiquiatr; 2018 Oct; 76(10):697-704. PubMed ID: 30427510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.
    Traboulsee A; Al-Sabbagh A; Bennett R; Chang P; Li DK; ;
    BMC Neurol; 2008 Apr; 8():11. PubMed ID: 18426595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.
    Ernst FR; Barr P; Elmor R; Wong SL
    Curr Med Res Opin; 2017 Dec; 33(12):2099-2106. PubMed ID: 28906152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS.
    Freedman MS; Brod S; Singer BA; Cohen BA; Hayward B; Dangond F; Coyle PK
    J Neurol; 2020 Jan; 267(1):64-75. PubMed ID: 31559532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
    Zivadinov R; Uxa L; Bratina A; Bosco A; Srinivasaraghavan B; Minagar A; Ukmar M; Benedetto Sy; Zorzon M
    Int Rev Neurobiol; 2007; 79():521-35. PubMed ID: 17531857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week.
    Coyle PK; Shang S; Xiao Z; Dong Q; Castrillo-Viguera C
    Mult Scler Relat Disord; 2018 May; 22():134-138. PubMed ID: 29679749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study.
    Uitdehaag B; Constantinescu C; Cornelisse P; Jeffery D; Kappos L; Li D; Sandberg-Wollheim M; Traboulsee A; Verdun E; Rivera V
    Ther Adv Neurol Disord; 2011 Jan; 4(1):3-14. PubMed ID: 21339904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
    Calabrese M; Bernardi V; Atzori M; Mattisi I; Favaretto A; Rinaldi F; Perini P; Gallo P
    Mult Scler; 2012 Apr; 18(4):418-24. PubMed ID: 21228025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis.
    Fusco C; Andreone V; Coppola G; Luongo V; Guerini F; Pace E; Florio C; Pirozzi G; Lanzillo R; Ferrante P; Vivo P; Mini M; Macrì M; Orefice G; Lombardi ML
    Neurology; 2001 Dec; 57(11):1976-9. PubMed ID: 11739812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.
    Freedman MS; Francis GS; Sanders EA; Rice GP; O'Connor P; Comi G; Duquette P; Metz L; Murray TJ; Bouchard JP; Abramsky O; Pelletier J; O'Brien F; ;
    Mult Scler; 2005 Feb; 11(1):41-5. PubMed ID: 15732265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous interferon β-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: Analysis of PRISMS and SPECTRIMS trials.
    Traboulsee A; Li D; Tam R; Zhao G; Riddehough A; Fang J; Dangond F; Kappos L;
    Mult Scler J Exp Transl Clin; 2017; 3(4):2055217317745340. PubMed ID: 29276624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
    Krueger JG; Kircik L; Hougeir F; Friedman A; You X; Lucas N; Greenberg SJ; Sweetser M; Castro-Borrero W; McCroskery P; Elkins J
    Adv Ther; 2016 Jul; 33(7):1231-45. PubMed ID: 27251051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
    Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered Immune Phenotypes and
    Devi-Marulkar P; Moraes-Cabe C; Campagne P; Corre B; Meghraoui-Kheddar A; Bondet V; Llibre A; Duffy D; Maillart E; Papeix C; Pellegrini S; Michel F
    Front Immunol; 2021; 12():628375. PubMed ID: 34113337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.